Back to results
US 7,744,891 B2Granted
Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
AssigneeBiogen Idec MA Inc.
InventorsJeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
Life of this patent
Estimating the term…
Abstract
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
Claims35
A method for reducing the humoral immune response in a subject comprising the step of
- administering a pharmaceutical composition which comprises a therapeutically effective amount of a LT-β-R blocking agent selected from the group consisting of:
- a soluble lymphotoxin-β receptor, an antibody directed against LT-β receptor, and an antibody directed against surface LT ligand to a subject that would benefit from a reduced humoral response, such that a reduced humoral response occurs in the subject.
A method for reducing the association of immune complexes and B cell follicles in a subject comprising administering an amount of an LT-β-R blocking agent selected from the group consisting of:
- a soluble lymphotoxin-β receptor, an antibody directed against LT-β receptor, and an antibody directed against surface LT ligand to a subject that would benefit from a reduced association of immune complexes and B cell follicles, such that a reduced association of immune complexes and B cell follicles occurs in the subject.
Dependencies are inferred from the claim text.